Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease

Table 2 Serum NfL level correlations with demographic, clinical, cognitive, and biochemical measures

	Whole sample rho(p value)	CTRrho(p value)	MCrho(p value)	AMCrho(p value)	SMCrho(p value)
N (N CSF)	60 (35)	18 (10)	42 (25)	20 (8)	22 (17)
Age	0.58 (< 0.001)	0.03 (0.92)	0.64 (< 0.001)	0.35 (0.13)	0.31 (0.16)
EYO	0.65 (< 0.001)	−0.25 (0.31)	0.75 (< 0.001)	0.41 (0.07)	0.29 (0.19)
MMSE	−0.65 (< 0.001)	0.24 (0.34)	−0.77 (< 0.001)	−0.30 (0.13)	−0.48 (0.02)
CDR-SOB	0.62 (< 0.001)	na	0.70 (< 0.001)	na	0.35 (0.18)
CSF NfL	0.70 (< 0.001)	0.22 (0.58)	0.72 (< 0.001)	0.66 (0.16)	0.41 (0.17)
CSF Aβ1–42	−0.43 (0.01)	0.04 (0.91)	−0.32 (0.12)	0.24 (0.57)	0.33 (0.19)
CSF total tau	0.59 (< 0.001)	−0.68 (0.03)	0.71 (< 0.001)	0.19 (0.65)	0.39 (0.12)
CSF p-tau	0.60 (< 0.001)	−0,56 (0.09)	0,71 (< 0.001)	0.19 (0.65)	0.41 (0.10)

Significant results are indicated in bold typeface
AMC asymptomatic mutation carriers, CTR non-carriers, CDR-SOB Clinical Dementia Rating sum of boxes, CSF cerebrospinal fluid, EYO estimated years from symptom onset, MC mutation carriers, MMSE Mini-Mental State Examination, na not applicable, NfL neurofilament light, p-tau phosphorylated tau, SMC symptomatic mutation carriers